L-Dopa and Parkinsonism.
D001479:Basal Ganglia / Q000378:metabolism; D001812:Blood-Brain Barrier; D002986:Clinical Trials as Topic; D003702:Delusions / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004296:Dopa Decarboxylase / Q000378:metabolism; D004298:Dopamine / Q000502:physiology*; D004358:Drug Therapy / Q000266:history; D049673:History, 20th Century; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D006899:Mixed Function Oxygenases / Q000378:metabolism; D008995:Monoamine Oxidase / Q000378:metabolism; D009069:Movement Disorders / Q000139:chemically induced; D009638:Norepinephrine / Q000096:biosynthesis; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D010627:Phenethylamines / Q000502:physiology; D013237:Stereoisomerism; D013378:Substantia Nigra / Q000378:metabolism; D013564:Sympathetic Nervous System / Q000187:drug effects
D007527:Isoenzymes; D010627:Phenethylamines; D004295:Dihydroxyphenylalanine; D006899:Mixed Function Oxygenases; D008995:Monoamine Oxidase; D004296:Dopa Decarboxylase; D004298:Dopamine; D009638:Norepinephrine